Flagship Pioneering, a company that conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability, has recognised Nancy Simonian, MD, CEO of Syros Pharmaceuticals (NASDAQ: SYRS), with the 2019 Pioneering Leader Award, it was reported yesterday.
Simonian joined Syros Pharmaceuticals as its founding CEO in 2012 and it is claimed that she has led its transformation from a discovery-stage company with a pioneering platform into a publicly traded clinical-stage company with multiple product candidates.
Noubar Afeyan, PhD, founder and CEO of Flagship Pioneering, said, 'Leveraging her successful and distinguished career in bringing new medicines to patients, Nancy has charted the course for Syros, built an impressive team, and positioned the company to deliver new therapies addressing cancer and monogenic diseases. During her tenure at Syros, Nancy has raised capital both privately and in the public markets to support new options for patients and create value for shareholders. In each step of Syros' journey, Nancy has shown pioneering spirit, strong instincts, and true leadership. We congratulate Nancy and look forward to Syros' bright future.'
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval